Abstract
Tritiated opioid ligands are essential tools for the identification of opioid receptors. This review deals with the syntheses of tritiated opioid peptide derivatives, including enkephalins, dynorphins, dermorphins, deltorphins and endomorphins, and also discusses tritium-labeled nonpeptide opioids. It additionally focuses on the relevance of tritium-labeled opioid compounds as research tools for investigating opioid receptor pharmacology. Agonists and antagonists are used for the characterization of new opioid ligands by means of radioreceptor binding assays. Further topics covered in this review are the distribution of the endogenous peptides in the central nervous system and peripheral tissues, and degradation studies of opioids in brain membrane preparations and the blood.
Keywords: Radiotracers, tritium, opioid receptors, opiates, opioid peptides.
Current Pharmaceutical Design
Title:Tritiated Opioid Receptor Ligands as Radiotracers
Volume: 19 Issue: 42
Author(s): Geza Toth and Jayapal Reddy Mallareddy
Affiliation:
Keywords: Radiotracers, tritium, opioid receptors, opiates, opioid peptides.
Abstract: Tritiated opioid ligands are essential tools for the identification of opioid receptors. This review deals with the syntheses of tritiated opioid peptide derivatives, including enkephalins, dynorphins, dermorphins, deltorphins and endomorphins, and also discusses tritium-labeled nonpeptide opioids. It additionally focuses on the relevance of tritium-labeled opioid compounds as research tools for investigating opioid receptor pharmacology. Agonists and antagonists are used for the characterization of new opioid ligands by means of radioreceptor binding assays. Further topics covered in this review are the distribution of the endogenous peptides in the central nervous system and peripheral tissues, and degradation studies of opioids in brain membrane preparations and the blood.
Export Options
About this article
Cite this article as:
Toth Geza and Mallareddy Reddy Jayapal, Tritiated Opioid Receptor Ligands as Radiotracers, Current Pharmaceutical Design 2013; 19 (42) . https://dx.doi.org/10.2174/138161281942140105170259
DOI https://dx.doi.org/10.2174/138161281942140105170259 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Focal Adhesion Kinase as a Cancer Therapy Target
Anti-Cancer Agents in Medicinal Chemistry Clinical Experiment of Mutant Herpes Simplex Virus HF10 Therapy for Cancer
Current Cancer Drug Targets The AMPAR Antagonist Perampanel Regulates Neuronal Necroptosis via Akt/GSK3β Signaling After Acute Traumatic Injury in Cortical Neurons
CNS & Neurological Disorders - Drug Targets NEDD4: A Promising Target for Cancer Therapy
Current Cancer Drug Targets Poly (ADP-Ribosyl) Polymerase 1 Inhibitors: A Patent Review
Recent Patents on Anti-Cancer Drug Discovery Transporters at CNS Barrier Sites: Obstacles or Opportunities for Drug Delivery?
Current Pharmaceutical Design DNA Methylation in Epithelial Ovarian Cancer: Current Data and Future Perspectives
Current Molecular Pharmacology Identification and Targeting of Tumor Escape Mechanisms: A New Hope for Cancer Therapy?
Current Pharmaceutical Design Lenalidomide in an in vitro Dendritic Cell Model for Malignant Gliomas
Anti-Cancer Agents in Medicinal Chemistry In Vivo Bio-imaging Using Chlorotoxin-based Conjugates
Current Pharmaceutical Design Carbohydrate-Metal Complexes and their Potential as Anticancer Agents
Current Medicinal Chemistry New and Highly Potent Antitumor Natural Products from Marine-Derived Fungi: Covering the Period from 2003 to 2012
Current Topics in Medicinal Chemistry Insights into the Role of mTOR/AMPK as a Potential Target for Anticancer Therapy
Current Drug Therapy Antineoplastic Effects of PPARγ Agonists, with a Special Focus on Thyroid Cancer
Current Medicinal Chemistry Early Genetic Changes Involved in Low-Grade Astrocytic Tumor Development
Current Molecular Medicine Nanoplatforms for Delivery of siRNA to the Eye
Current Pharmaceutical Design Non-Viral Delivery of RNA Interference Targeting Cancer Cells in Cancer Gene Therapy
Current Gene Therapy Development of Amino Acid-Based Radiopharmaceuticals for Tumor Imaging
Mini-Reviews in Medicinal Chemistry Lysosomal Storage Diseases and the Blood-Brain Barrier
Current Pharmaceutical Design PEGylated Peptide-Based Imaging Agents for Targeted Molecular Imaging
Current Protein & Peptide Science